NCT Number: NCT00022763
T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents
This study will evaluate T-20 in children.
Looking for future studies?
Notify MeKey information
Conditions
Age range
3 year–16 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Children's Hosp Los Angeles, Los Angeles, California, United States
About this study
Children are stratified by age group (3 through 11 years and 12 through 16 years). Samples for HIV-1 genotype and phenotype resistance testing are obtained at screening to aid in the selection of concomitant antiretrovirals. Simultaneous to initiating T-20, all patients begin a "new" optimized antiretroviral regimen based on the patients' prior treatment history, historical resistance testing results, and the results of the testing performed at screening. Patients are followed for safety and other assessments at Weeks 1, 2, and 4, then monthly through Week 24 and bimonthly through Week 48. Pharmacokinetic sampling at selected study visits are performed.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients may be eligible for this study if they:
- Are 3 through 16 years of age and have the consent of parent or guardian.
- Have a viral load of at least 5000 copies/ml.
- Have taken at least 2 of the 3 licensed anti-HIV drug classes for at least 3 months.
- Have been on stable therapy for at least 4 weeks.
Treatment and study plan
Primary outcomes
-
Area Under the Plasma Concentration Time Curve (AUC) From 0-12 Hours for Enfuvirtide and Its Metabolite (Ro 50-6343)
Time frame: Pre-dose (time 0), and 2, 4, 8, and 12 hours post-dose (Week 1)
The Area Under the Plasma Concentration-Time Curve (AUC) is a measure of the plasma concentration of the drug over time. It is used to characterize drug absorption. AUC was calculated from plasma concentration-time data (on Day 7) using standard non-compartmental pharmacokinetic methods.
Secondary outcomes
-
Maximum Plasma Concentration (Cmax) for Enfuvirtide and Its Metabolite (Ro 50-6343)
Time frame: Pre-dose (time 0), and 2, 4, 8, and 12 hours post-dose (Week 1)
The Plasma Concentration (Cmax) is defined as maximum observed analyte concentration. Cmax was calculated from plasma concentration-time data (on Day 7) using standard non-compartmental pharmacokinetic methods.
-
Time to Maximum Plasma Concentration (Tmax) for Enfuvirtide
Time frame: Pre-dose (time 0), and 2, 4, 8, and 12 hours post-dose (Week 1)
Tmax is defined as actual sampling time to reach maximum observed analyte concentration.
-
Minimum Plasma Concentration (Ctrough) for Enfuvirtide and Its Metabolite (Ro 50-6343)
Time frame: Pre-dose (time 0), and 2, 4, 8, and 12 hours post-dose (Week 1)
Ctrough is defined as the lowest concentration that a drug reaches before the next dose is administered.
-
AUC12h Ratio of Enfuvirtide Metabolite (Ro 50-6343)/ENF (Ro 29-9800)
Time frame: Pre-dose (time 0), and 2, 4, 8, and 12 hours post-dose (Week 1)
The ratio of the area under plasma concentration-time curve from time 0 to 12 hours of Enfuvirtide Metabolite (Ro 50-6343) versus enfuvirtide was calculated.
-
Number of Participants With Adverse Events (AEs) and Serious AEs
Time frame: Up to Week 4 after discontinuation of therapy
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a significant medical event.
-
Number of Participants With Treatment Emergent Grade 3 or Grade 4 Laboratory Abnormalities
Time frame: Up to Week 96
Pediatric AIDS Clinical Trials Group (PACTG) toxicity grading scale was used for reviewing and grading clinically significant laboratory abnormalities. PACTG Grade 3 and Grade 4 were considered Severe and life threatening, respectively.
-
Number of Participants Who Died
Time frame: Up to Week 96
-
Number of Participants Who Prematurely Withdrew Due to AE
Time frame: Up to Week 96
-
Number of Participants With Worst Local Injection Site Reactions
Time frame: Up to Week 96
Numbers of Participants With worst local injection site reactions were reported. Localized injection site reactions like erythema, induration, pruritus, nodule and cyst, and ecchymosis were recorded.
Sponsors and collaborators
Lead sponsor
Hoffmann-La Roche
Industry
Collaborators
- Trimeris
Registry information
Official study title
A Phase I/II Pharmacokinetic and Safety Study of T-20 in Combination With an Optimized Background in HIV Infected Children and Adolescents
Important dates
- Study start
- 2001
- Primary completion
- 2004
- First posted
- Aug 31, 2001
- Registry last updated
- Feb 15, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants
NCT03048422
Blood-Borne Infections, Communicable Diseases
Jacksonville, Florida, United States
View Trial DetailsA Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab
NCT05388474
Blood-Borne Infections, Communicable Diseases
Los Angeles, California, United States
View Trial DetailsSafety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine
NCT03284710
Blood-Borne Infections, Communicable Diseases
Maputo, Mozambique
View Trial DetailsSafety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection
NCT02591420
Blood-Borne Infections, Communicable Diseases
Kericho, Kenya
View Trial Details